obesity-congress-diabetes-congress-2018-posters

2 / 22

Page 48
O c t o b e r 1 5 - 1 6 , 2 0 1 8 | T o k y o , J a p a n
Obesity Congress 2018, Diabetes Congress 2018 & Vaccines Congress 2018 Biomedical Research | ISSN: 0976-1683| Volume 29
2nd WORLD OBESITY CONGRESS
2nd WORLD VACCINES AND IMMUNOLOGY CONGRESS
&
&
DIABETES AND ENDOCRINOLOGY
International Conference on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Devrishov D et al., Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C5-014
THE PRESENT AND FUTURE OF VACCINEAL
PREVENTION OF ANIMAL BRUCELLOSIS
Devrishov D, Marzanova S and Devrishov A
Moscow State Academy of Veterinary Medicine and Biotechnology- MVA K I Skry-
abin, Russia
The effectiveness of corrective measures for brucellosis is largely deter-
mined by the quality of epidemiological surveillance and the effective-
ness of vaccine prevention. Used live vaccines do not fully protect against
infection, at the same time they pose a potential risk of Brucella infection in
animals with low immune resistance and post-vaccination complications and
pose a danger to livestock breeders and the population consuming untreated
products from vaccinated animals. Inactivated vaccines did not find practi-
cal application due to insufficient efficacy and high reactogenicity. Consider-
ing that vaccination is the basis for the prevention of Brucella infection, we
conducted studies on the selection of strains, developed and experimentally
tested a split conjugated biosafe vaccine based on immunogenically active
subcellular and soluble peptides of three Brucella strains: B.melitensis and
two strains of Brucella bovis biotype. To stimulate specific immunity, Brucella
antigens were conjugated to an immunoprotector. The immunoprotector was
obtained from a culture of B lymphocytes sensitized with Brucella antigens.
Activity control was assessed by immunostimulating of the mechanisms of
cellular and humoral immunity and immunogenic activity of the vaccine in
guinea pigs. The immunogenic activity of the declared vaccine was studied
on guinea pigs weighing 300-400 g, which were subcutaneously injected into
the groin area with test specimens of vaccines at a dose of 0.5 cm3. After
four weeks vaccinated guinea pigs were infected with a virulent culture of B.
bovis 10 in an infectious dose (ID). At the same time, non-vaccinated (control)
guinea pigs were infected. 30 days after infection, guinea pigs were killed and
bacteriological seeding of lymph nodes and organs on Brucella agar and Bru-
cella broth was performed. Seeding was sterile in 100% of vaccinated guinea
pigs. In seeding from control unvaccinated guinea pigs in 100% of cases, a
culture of Brucella of the infecting strain was isolated. As, a result, immuni-
zation of the split-conjugated brucellosis vaccine activates the cellular and
humoral immune response, enhancing the induction of specific antibodies.
Advantages of a split-conjugated vaccine: biosafety, protection of immunized
animals from infection with brucella during experimental infection, reliably
exceeds the specific efficiency of live anti-brucella vaccines from strains B.
abortus 19 and B. melitensis Rev-1.
Devrishov D is a Doctor of Biological Sciences, PhD of
Veterinary Sciences, Professor, Corresponding Mem-
ber of the Russian Academy of Sciences, has over 270
scientific publications, is the Head of the Department
of Immunology and Biotechnology, Editor of the scien-
tific and practical journal “Veterinary Medicine” Davud
D.
BIOGRAPHY